Breast Cancer

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

Biostatistics for clinician researchers 2: Choosing the right statistical test

What is a SR and MA, when to do it and when not

Biostatistics for clinician researchers 2: Survival and K-M analysis

Doable clinical research in LMICs

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Adjuvant radiotherapy has no benefit following radical prostatectomy

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC